Su LJ - Search Results

1

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.

Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM. Flaig TW, et al. Among authors: su lj. Invest New Drugs. 2007 Apr;25(2):139-46. doi: 10.1007/s10637-006-9019-2. Epub 2006 Nov 1. Invest New Drugs. 2007. PMID: 17077998 Clinical Trial.

2

Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.

Flaig TW, Su LJ, Harrison G, Agarwal R, Glodé LM. Flaig TW, et al. Among authors: su lj. Int J Cancer. 2007 May 1;120(9):2028-33. doi: 10.1002/ijc.22465. Int J Cancer. 2007. PMID: 17230508 Free article.

3

A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.

Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. Flaig TW, et al. Among authors: su lj. Prostate. 2010 Jun 1;70(8):848-55. doi: 10.1002/pros.21118. Prostate. 2010. PMID: 20127732 Clinical Trial.

4

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer.

Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET. Kessler ER, et al. Among authors: su lj. Integr Cancer Ther. 2018 Dec;17(4):1103-1108. doi: 10.1177/1534735418803755. Epub 2018 Oct 5. Integr Cancer Ther. 2018. PMID: 30289005 Free PMC article. Clinical Trial.

5

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Yang X, et al. Among authors: su lj. Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258. Epub 2012 Nov 21. Clin Cancer Res. 2013. PMID: 23172881 Free PMC article.

6

VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.

Li Y, Yang X, Su LJ, Flaig TW. Li Y, et al. Among authors: su lj. Oncol Rep. 2010 Oct;24(4):1019-28. doi: 10.3892/or.2010.1019. Oncol Rep. 2010. PMID: 20811684

7

Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.

Li Y, Yang X, Su LJ, Flaig TW. Li Y, et al. Among authors: su lj. Urology. 2011 Jul;78(1):233.e7-13. doi: 10.1016/j.urology.2011.02.041. Epub 2011 Apr 29. Urology. 2011. PMID: 21529900 Free PMC article.

8

miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2.

Yang X, Bemis L, Su LJ, Gao D, Flaig TW. Yang X, et al. Among authors: su lj. Biores Open Access. 2012 Apr;1(2):55-62. doi: 10.1089/biores.2012.9903. Biores Open Access. 2012. PMID: 23514806 Free PMC article.

9

Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.

Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Flaig TW, et al. Among authors: su lj. BJU Int. 2009 Jun;103(12):1729-37. doi: 10.1111/j.1464-410X.2009.08367.x. Epub 2009 Feb 10. BJU Int. 2009. PMID: 19220256

10

The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model.

Yang X, Su LJ, La Rosa FG, Smith EE, Schlaepfer IR, Cho SK, Kavanagh B, Park W, Flaig TW. Yang X, et al. Among authors: su lj. Bladder Cancer. 2017 Jul 27;3(3):201-210. doi: 10.3233/BLC-170096. Bladder Cancer. 2017. PMID: 28824948 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page